News

AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products…
Read More...

GSK plc announced the US Food and Drug Administration (FDA) has granted a Fast Track designation for its Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of…
Read More...

Xentria Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, and Meitheal Pharmaceuticals, Inc., announced an exclusive…
Read More...

Innovent Biologics, Inc. and RemeGen Co., Ltd. announced that they entered into a clinical trial collaboration and supply agreement with for the combination therapies of TYVYT…
Read More...

Brii Biosciences Limited announced that it entered into definitive agreements with Qpex Biopharma and third parties in connection with the acquisition of Qpex by Shionogi. Under the…
Read More...

Talaris Therapeutics, Inc. and Tourmaline Bio, Inc. announced that the companies have entered into a definitive agreement under which Tourmaline will combine with Talaris in an…
Read More...

ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and a leading Japanese…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) for the treatment of…
Read More...

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, officially opened its…
Read More...

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary…
Read More...

Astellas Pharma Inc. announced a research collaboration and exclusive option agreement to discover multiple innovative protein degraders. Under the terms of the agreement, the two…
Read More...

Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and…
Read More...

Sandoz announced the launch of a global roadmap to increase patient access to biologic medicines. The Act4Biosimilars Action Plan is part of the Act4Biosimilars initiative, founded by…
Read More...

Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)…
Read More...

Fresenius Kabi announced the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict. Fresenius Kabi Vasopressin Injection, USP is an…
Read More...

Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced…
Read More...

DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotides (FALCON) platform,…
Read More...

ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban…
Read More...